Recently, the Wang Dao Wen’s team of Huazhong University of Science and Technology published a paper titled “ Chinese Society of Cardiology guidelines on the diagnosis and treatment of adult fulminant myocarditis”. This is the first release of diagnostic and treatment guidelines for adult fulminant myocarditis in China. This guideline points out that the cytokine storm caused by the excessive activation of innate immunity and the rapid release of inflammatory factors by immune cells, also known as the „inflammatory storm“, is the core cause of the rapid onset, rapid progression, severe condition, and high mortality rate of fulminant myocarditis. It systematically summarizes the clinical evaluation content of patients with fulminant myocarditis from the collection of medical history, clinical symptoms, and related examinations, Thus, the clinical diagnostic criteria and diagnostic process for fulminant myocarditis were established, and a “life support-based comprehensive… 

25. März 2024: RCSI-Forschungen haben ergeben, dass Venetoclax, ein derzeit gegen Leukämie zugelassenes Medikament, Vorteile für Patienten mit multiplem Myelom hat, wenn es in Kombination mit einem anderen Medikament angewendet wird. Diese Entdeckung eröffnet neue Möglichkeiten zur Behandlung der derzeit unheilbaren Krankheit. Das Multiple Myelom (MM) ist eine Blutkrebsart, die in Irland jedes Jahr bei etwa 400 Menschen neu diagnostiziert wird. Trotz der Fortschritte in der Behandlung in den letzten Jahren ist sie nach wie vor unheilbar. Die Suche nach innovativen Behandlungsstrategien ist von entscheidender Bedeutung, insbesondere für Patienten, deren Krebs gegen die Standardbehandlung resistent ist. In der neuen, in Haematologica veröffentlichten Studie machten sich Forscher der RCSI-Abteilung für Physiologie und Medizinische Physik und des Beaumont RCSI Cancer Center daran, komplementäre Medikamente zu identifizieren, die die Wirksamkeit von Venetoclax, einem zur Verwendung bei Leukämie zugelassenen Medikament, für die MM-Behandlung verbessern… 

Nucleus Genomics, the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone. DNA and health are inextricably linked, but profound insights into how DNA can shape health are missing from healthcare. Customers who’ve previously done microarray genetic testing with older testing companies can upload their DNA data onto Nucleus’ platform to receive greater insights into their genetic risk for diseases like type 2 diabetes, breast cancer, and many more. Nucleus further personalizes these risk assessments by integrating personal and lifestyle factors into their analysis — such as age, cholesterol levels, blood pressure, and BMI. The company — which raised a total of $18 million in seed funding in 2022 from venture capital firms such as Alexis Ohanian’s Seven Seven Six and Peter Thiel’s Founders Fund… 

NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 3,054,609 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”), and accompanying warrants (the “Accompanying Warrants”) to purchase up to 3,054,609 shares of Common Stock at a combined offering price of $2.901 per Share and Accompanying Warrant and pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 5,565,027 shares of Common Stock and Accompanying Warrants to purchase up to 5,565,027 shares of Common Stock at a combined offering price of $2.900 per share underlying each Pre-Funded Warrant and Accompanying Warrant, which equals the offering price per… 

Chemomab has gained a new EU patent for CM-101 covering its use in liver diseases including PSC, adding to the robust patent estate in major territories. Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis